ICH Q9(R1) is the revised guideline on Quality Risk Management (QRM) adopted by the International Council for Harmonisation (ICH) to improve how the pharmaceutical industry applies risk management principles throughout the product lifecycle.
While the fundamental core framework of the original ICH Q9 remains intact, Revision 1 (R1) directly targets four major problem areas identified in industry practice.
Four Key Focus Areas in ICH Q9(R1)
Subjectivity in Risk Assessments
Issue: Teams often manipulate severity, occurrence, or detection scoring to reach a predetermined “acceptable” outcome (confirmation bias).
Guidance: Calls for science-based decision-making, clear rating scales, diverse cross-functional teams, and active identification of cognitive biases.
Supply Chain & Product Availability Risks
Issue: Traditional QRM focused heavily on site-level batch failures, overlooking vulnerabilities leading to drug shortages.
Guidance: Integrates supply continuity into QRM. Manufacturers must evaluate manufacturing complexity, single-source suppliers, capacity constraints, and supply-chain maturity to protect patient supply.
Formality in Quality Risk Management
Issue: Many firms applied high-formality, burdensome documentation to minor issues, while sometimes using informal assessments for high-risk decisions.
Guidance: Clarifies that formality is a spectrum, not a binary choice. The level of formality (resources, documentation, tool complexity) must be proportional to the level of risk and uncertainty involved.
Risk-Based Decision-Making (RBDM)
Issue: Lack of structured, transparent frameworks for everyday decision-making (deviations, change controls, CAPAs).
Guidance: Defines clear expectations for how risk assessments directly inform decision outcomes, documenting rationale and handling residual risk.
Comparison: ICH Q9 vs. ICH Q9(R1)
| Area | Original ICH Q9 (2005) | ICH Q9(R1) (2023) |
| Formality | Mentioned that effort should match risk, but lacked criteria. | Clear spectrum of formality with defined criteria on when to use low vs. high formality. |
| Subjectivity | Recognized subjectivity as a challenge. | Explicit section detailing causes of subjectivity (bias, lack of data) and how to mitigate them. |
| Shortages & Supply | Not explicitly addressed. | Formally links product quality risks with drug shortages and supply interruptions. |
| Risk-Based Decisions | General concept embedded in QRM. | Dedicated guidance on structured Risk-Based Decision-Making (RBDM). |
| Digital/Hazard Tools | Traditional tools (FMEA, HACCP, PHA, Ishikawa). | Clarifies practical selection of tools matching the complexity and formality required. |